PolyMedix, Inc. To Present At American Society of Microbiology 109th General Meeting

PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, will display a poster at 10:45AM on Tuesday May 19th at the 109th General Meeting of the American Society of Microbiology. The poster will describe the latest information on the mechanism of action of PolyMedix arylamide foldamers.

Titled “Antimicrobial Systemic Antibiotics: Small Molecule Mimics of Host Defense Proteins,” the poster describes the series of arylamide foldamers that are designed to mimic the activities of naturally occurring antimicrobial peptides (synthetic small molecule defensin mimetics). These molecules showed high levels of activity against both Gram-positive and Gram-negative bacteria with minimal toxicity mammalian cells. The goal of this study was to understand their mechanism of action and lack of toxicity.

“This research supports the commitment that PolyMedix has to continue to discover new ways to address life threatening diseases,” said Dr. Richard Scott, Vice President of Research at PolyMedix. “It is the dedication, commitment, and collaboration with our scientific partners that allows us to continue to explore molecules that could be effective against other infections. It is a wonderful opportunity to present these findings in Philadelphia at the ASM General Meeting.”

PolyMedix’s lead defensin-mimetic antibiotic compound is PMX-30063, currently in Phase I clinical development. On December 10, 2008, PolyMedix announced the results of the first Phase I human clinical study with PMX-30063. The results of that study suggest that it should be possible to achieve clinically therapeutic levels with daily doses of PMX-30063 which are lower than those associated with any adverse effects seen in the single dose study. The initial indication planned for PMX-30063 is as a treatment for pan-Staphylococcal infections, including MRSA (methicillin-resistant Staphylococcus aureus).

Meeting Summary of the ASM General Meeting

The General Meeting program provides interest sessions on areas of Policy, Education, History, Communications, International Affairs, Minority Affairs, Women’s Affairs, Career Development, and the Academy. Details on specific sessions may be seen through the home webpage: http://www.gm.asm.org

About PolyMedix, Inc.

PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix’s compounds are based on biomimetics: non-peptide small molecule drug candidates that mimic the activity of proteins. The Company’s antibiotic compounds, including PMX-30063 – small molecule mimetics of human host-defense proteins - have a mechanism of action distinct from those of current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. The Company’s goal is to develop these as rapidly acting antibiotics for serious systemic and local infections. The Company plans to continue the development of polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. The Company’s heptagonist compounds, including PMX-60056, reverse the activity of both heparin and Low Molecular Weight Heparins, with the goal of developing an antagonist drug that is safer and easier to use than currently approved therapy. For more information, please visit PolyMedix on its website at www.polymedix.com.

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and that could cause PolyMedix’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends”, “goal”, “potential,” “may”, and similar expressions. Among other things, there can be no assurance that PolyMedix’s compounds will enter or successfully complete clinical testing or be granted regulatory approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks, uncertainties and assumptions is included in PolyMedix’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.